FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure® Cell Therapy

Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure® Cell Therapy

Celyad receives certification for C-Cure® non-clinical data from the European Medicines Agency (EMA)

Celyad receives certification for C-Cure® non-clinical data from the European Medicines Agency (EMA)

Celyad notifies the European Medicines Agency (EMA) of its intention to file a Marketing Authorization Application (MAA) for C-Cure®

Celyad notifies the European Medicines Agency (EMA) of its intention to file a Marketing Authorization Application (MAA) for C-Cure®

Joint-PR-Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Production of C-Cure®

Joint-PR-Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Production of C-Cure®

Celyad receives clearance from the US FDA on its CHART-2 Phase III IND

Celyad receives clearance from the US FDA on its CHART-2 Phase III IND

Celyad announces the publication of its CHART-1 trial design methods paper in the European Journal of Heart Failure

Celyad announces the publication of its CHART-1 trial design methods paper in the European Journal of Heart Failure

Celyad initiates the certification by the EMA of the non-clinical data of C-Cure®

Celyad initiates the certification by the EMA of the non-clinical data of C-Cure®

Celyad completes final patient infusion in CHART-1 Phase III trial

Celyad completes final patient infusion in CHART-1 Phase III trial

Cardio3 BioSciences successfully completes futility analysis of lead cardiac cell therapy, C-Cure®

Cardio3 BioSciences successfully completes futility analysis of lead cardiac cell therapy, C-Cure®

Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure® market registration with Paediatric Investigation Plan waiver from EMA

Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure® market registration with Paediatric Investigation Plan waiver from EMA

Cardio3 BioSciences announces the enrolment of the 240th patient for its CHART-1 phase III clinical trial for the treatment of heart failure

Cardio3 BioSciences announces the enrolment of the 240th patient for its CHART-1 phase III clinical trial for the treatment of heart failure